Aquestive Therapeutics (AQST) Expected to Announce Earnings on Tuesday

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Aquestive Therapeutics to post earnings of ($0.17) per share and revenue of $12.23 million for the quarter. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to analysts' expectations of $13.11 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Aquestive Therapeutics Stock Performance

AQST opened at $2.83 on Tuesday. The stock has a market capitalization of $279.80 million, a price-to-earnings ratio of -6.29 and a beta of 2.59. Aquestive Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $5.80. The company has a fifty day moving average of $2.78 and a 200 day moving average of $3.59.

Analyst Upgrades and Downgrades

AQST has been the topic of a number of research analyst reports. Alliance Global Partners reiterated a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, April 2nd. Finally, Lake Street Capital decreased their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $10.67.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.